Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
Neil P. Shah(University of California, Los Angeles), John Nicoll, Bhushan Nagar(University of California, Berkeley), M. Gorre, Ronald Paquette, John Kuriyan(Howard Hughes Medical Institute), Charles L. Sawyers(University of California, Los Angeles)
Cited by 1,623Open Access
Abstract
Related Papers
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Hagop Kantarjian, Charles L. Sawyers, Andreas Hochhaus et al.|New England Journal of Medicine|2002|2k